Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vidofludimus hemicalcium (4sc-101; SC12267) is an orally active compound that acts as a dihydroorotate dehydrogenase (DHODH) inhibitor and serves as a novel modulator of the farnesoid X receptor (FXR). This immunomodulatory agent is utilized in the research of autoimmune disorders, including inflammatory bowel disease (IBD), and is explored for its potential in fatty liver disease research through FXR targeting.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,670.00 | |
50 mg | 6-8 weeks | $ 2,180.00 | |
100 mg | 6-8 weeks | $ 2,800.00 |
Description | Vidofludimus hemicalcium (4sc-101; SC12267) is an orally active compound that acts as a dihydroorotate dehydrogenase (DHODH) inhibitor and serves as a novel modulator of the farnesoid X receptor (FXR). This immunomodulatory agent is utilized in the research of autoimmune disorders, including inflammatory bowel disease (IBD), and is explored for its potential in fatty liver disease research through FXR targeting. |
Synonyms | 4sc-101 hemicalcium, SC12267 hemicalcium, 4sc-101 hemicalcium ; SC12267 hemicalcium |
Molecular Weight | 375.4 |
Formula | C20H18FNO4.1/2Ca |
CAS No. | 1354012-90-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Vidofludimus hemicalcium 1354012-90-0 4sc-101 hemicalcium ; SC-12267 SC12267 SC-12267 4sc-101 hemicalcium Vidofludimus SC12267 hemicalcium QC 308 HCl QC308 hydrochloride QC 308 hydrochloride 4sc-101 hemicalcium ; SC12267 hemicalcium QC308 HCl 4sc-101 QC-308 hydrochloride 4sc-101 hemicalcium ; SC 12267 SC 12267 4sc-101 hemicalcium ; SC12267 4sc-101 hemicalcium ; SC12267 hemicalcium inhibitor inhibit